1. INVESTOR UPDATE 3Q | 2015

2. KEY TO OUR SUCCESS Exactech sustains a customer centric culture that creates customer loyalty

3. Investment Highlights Targeting $46 billion global biomedical device market Consistent long term growth 2x as fast as overall market Broad product portfolio of innovative products Robust product pipeline expanding company’s market Highly experienced orthopaedic management team Growing sales organization with increasing rep productivity Proven track record of creating long-term profitable growth

4. Our story. Surgeon founded Innovation to improve patient outcomes Surgeon input driven Collaborative relationship with sales force Financial stability

5. Proven track record of growth. (annual sales $ mil) 2010 Vertical Supply Acquisitions 2008 Entered Spine Market 2005 Equinoxe ® Shoulder Launch 2001 First Bone Cement Sales 1998 Entered Biologics Market Internal Manufacturing 1996 IPO 1994 First Knee Implant Sales 1985 Exactech Founded 2008 French Distributor Acquisition 2010-12 Expanded OUS Direct Operations 2014 Launch of ExactechGPS ® CAS Technology Acquisition

6. Source: OrthoWorld Orthopaedic Industry Annual Report 2015 Targeting Highly Attractive Markets

7. 2014 sales by business unit based on 2014 SEC 10-K Broad Portfolio of Innovative Products 2014 Sales by Business Unit ($ millions)

8. PRODUCTS With emphasis on new products currently being launched and to be launched over the next twelve months.

9. Optetrak ® Logic Knee System 30-year evolved design Streamlined instrumentation Multiple constraint options for primary & revision knees with NCM poly ExactechGPS ® Comprehensive total knee system with excellent clinical results.

11. Extremities Comprehensive platform system Embraces the Glenoid with unique bone-conserving solutions Pipeline of strong clinical publications Equinoxe ® Platform Shoulder redefining intra-operative flexibility, solving clinical challenges surgeons face

13. Hip Alteon ® tapered wedge and Neck Preserving stem designs Direct anterior approach instrumentation Acetabular cup with InteGrip ® technology Addressing the major philosophies of THA

15. Biologics Optecure ® / Opteform ® Allograft DBM products Accelerate ® Cell Therapy Cartilage repair technology under development Innovative, clinically effective biomaterials

16. New Biologic Product Reveille

17. Cement Cemex ® bone cement InterSpace ® pre-formed hip, knee and shoulder spacers InterSpace ® high release Safety, simplicity and efficacy

19. Spine Proliant ® pedicle screw system Silverbolt ® MIS screw system Octane ® PEEK cervical interbody; Gibralt ® posterior cervical Octane ® Lumbar Interbody Expanding portfolio of spinal innovations

21. ExactechGPS ® Implant alignment accuracy & precision Ease of use, cost-effective Surgeon maintains operating control Competitive marketing edge for hospitals Documented clinically improved constructs Excellent teaching tool Guided, personalized surgery provides an effective solution to unmet needs

23. New Products Summary – 12 Month Horizon Knee - 2: Revision System; RBK in U.S. Extremities - 4: Humerus Reconstruction; Inset Glenosphere; Ceramic Glenosphere; Ankle Hip - 2: Monobloc Revision Stem; Revision Acetabulum Biologics - 1: Autologous Cartilage Preparation Cement - 1: Tapered Wedge Interspace Spine - 5: Two Cervicle Plates; Three Interbody Devices GPS - 3: Version 2 (tablet based); GPS for Revision Knee; GPS for Shoulder Total of eighteen new products.

24. Exactech manufacturing Manufacturing in U.S. Up to 80% in-house. Lean initiatives in manufacturing and entire company.

25. US  Network of independent sales agencies  Managed by corporate regional vice presidents OUS  Network of independent distributors and wholly- owned subsidiaries  Direct operations in: Canada, UK, Spain, Germany, France, Japan, China Our reach.

26. FY Guidance $246-250MM; +2-4% constant currency FY’15 Guidance $1.16-1.20 Financial Trends

27. $ and shares in millionsJun- 15Dec-14 Cash$14.9$10.1 Debt$21.8$23.3 Shareholders’ Equity$219.8$211.4 Common Shares Outstanding (1) 14.2 Market Value (2) $270.10 (1) Fully diluted shares as reported in 8.5.15 10-Q (2) Share price of $18.70 as of 8.6.15 close Summary Financial Data

28. Why Exactech. Understanding of market needs/opportunities Major new product introductions Sales channel opportunities Proven financial performance and corporate stability

29. Thank you.

30. This presentation contains various forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 which represent the company’s expectations or beliefs concerning future events. These forward looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation, including without limitation an ongoing investigation by the U.S. Department of Justice of various practices within the orthopaedic industry, as well as other risks and uncertainties including those described in the company’s filings with the Securities and Exchange Commission. You should carefully consider these risks before making a decision to invest in our securities. Results actually achieved may differ materially from expected results included in these statements. DISCLAIMER/FORWARD LOOKING STATEMENTS